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Introduction: Preeclampsia (PE) is a prevalent clinical entity in pregnancy, which is responsible for 
substantial maternal-fetal morbidity and mortality. Prediction of PE could offer a window of opportunity 
for intervention during pregnancy, making it potentially possible to prevent adverse obstetric and 
neonatal outcomes. As screening for PE based only on maternal history has shown to be insufficient, 
measurement in early pregnancy of a variety of markers implicated in the pathophysiology of PE has 
been proposed to predict its development. Because any single biomarker is unlikely to be effective in 
prediction of the onset of a disorder as heterogeneous as PE, it is under investigation which 
combinations of tests, such as ultrasound and serum markers, would raise the effectiveness of history 
and physical-based screening. The accuracy of models for PE prediction, either maternal history-based 
or combined with biomarkers, is unknown in the Portuguese population.  
Objective: To evaluate the performance of a first trimester aneuploidy screening program for PE 
prediction in a Portuguese obstetric population, when performed under routine clinical conditions.  
Material and Methods: Retrospective cohort study of 5672 pregnant women who underwent routine 
first trimester aneuploidy screening in a Portuguese university hospital from January 2009 to June 2013. 
Logistic regression-based predictive models were developed for prediction of PE based on maternal 
characteristics, crown-rump length (CRL), nuchal translucency thickness (NT), and maternal serum levels 
of pregnancy-associated plasma protein-A (PAPP-A) and free beta-subunit of human chorionic 
gonadotropin (free β-hCG).  
Results: At a false-positive rate of 5/10%, the detection rate for early-onset (EO-PE) and late-onset (LO-
PE) PE was 31.4/45.7% and 29.5/35.2%, respectively. Although both forms of PE were associated with 
decreased PAPP-A, logistic regression analysis revealed significant contributions from maternal factors, 
free β-hCG, CRL, and NT, but not PAPP-A, for prediction of PE.  
Conclusions: Our findings support that both clinical forms of EO-PE and LO-PE can be predicted using a 
combination of maternal history and biomarkers assessed at first trimester aneuploidy screening. 
However, detection rates were modest, suggesting that models need to be improved with additional 
markers not included in the current aneuploidy screening programs. 
Contacts: Cláudia Teixeira, médica interna de patologia clínica, CHP; doutoranda em Investigação Clínica 
e em Serviços de Saúde, FMUP: claudiateixeira@med.up.pt. 
